Beike Biotech and its parent company terminate the associated transaction of cooperation with Sionx's new crown virus vaccine license

September 27, one hundred grams of biological announcement that the parent company and the Changchun High-tech will end with the letter Biotechnology Co.

The aforesaid termination of related transactions was reviewed and approved at the eighteenth meeting of the fourth board of directors of Beike Biotech on September 27, 2021, and related directors have abstained from voting

As of the date of this announcement, Changchun Hi-tech and Beike Biotech have not carried out the relevant research work involved in the transaction, and have not made actual investment in the research and development of the new coronavirus vaccine (PIV-5 vector).

In June 2021, Beike Biotech and its parent company, Changchun High-tech, intends to obtain the new coronavirus vaccine (PIV-5 vector) and the vaccine (PIV-5 vector) related technologies developed for the new coronavirus mutant strain in the license The exclusive licensing rights in the region and the exclusive production rights in other Asian regions and Oceania regions outside the licensed region have signed the "Licensing Cooperation Agreement

Sianxin is a 25.

Affected by recent virus mutations at home and abroad and changes in the epidemic situation, in order to ensure the smooth progress of the development of the new coronavirus vaccine (PIV-5 vector), Changchun High-tech and Baike Biological plans to challenge Sion's new coronavirus vaccine (PIV-5).

The terms of early termination in the license cooperation agreement between Changchun High-tech, Beike Biotech and Sion on the new coronavirus vaccine (PIV-5 carrier) license include the early termination of the agreement "with the written consent of all parties

At the same time that Beike Biosciences terminated the signing of the agreement, Changchun High-tech also terminated the agreement.

In the next 12 months, Beike Biotech has no plans to cooperate with Sianxin